Pharma Mar S.A./€PHM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Pharma Mar S.A.
Pharma Mar S.A. is a biopharmaceutical company based in Madrid, Spain, specializing in the research, development, and commercialization of marine-derived drugs. The company's core focus is on oncology, where it develops and produces antitumor drugs. Its product portfolio includes compounds such as Yondelis, Aplidin, and Zepzelca, each targeting various forms of cancer. Founded in 1986, Pharma Mar is part of the pharmaceutical group Zeltia. The company leverages its unique access to marine biodiversity to create differentiated products, positioning itself distinctively within the pharmaceutical industry. Pharma Mar operates globally, with a significant foothold in both European and international markets.
Ticker
€PHM
Sector
Primary listing
BME
Employees
500
Headquarters
Website
Pharma Mar S.A. Metrics
BasicAdvanced
€1.6B
-
-
-0.09
€0.80
0.90%
Price and volume
Market cap
€1.6B
Beta
-0.09
52-week high
€104.76
52-week low
€41.41
Average daily volume
55K
Dividend rate
€0.80
Financial strength
Current ratio
2.841
Quick ratio
2.142
Long term debt to equity
19.311
Total debt to equity
25.505
Dividend payout ratio (TTM)
33.20%
Interest coverage (TTM)
7.69%
Profitability
EBITDA (TTM)
35.925
Gross margin (TTM)
94.98%
Net profit margin (TTM)
22.20%
Operating margin (TTM)
16.61%
Effective tax rate (TTM)
-27.77%
Revenue per employee (TTM)
€380,000
Management effectiveness
Return on assets (TTM)
5.91%
Return on equity (TTM)
21.94%
Valuation
Dividend yield (TTM)
0.90%
Growth
Revenue change (TTM)
19.18%
3-year revenue growth (CAGR)
-6.64%
3-year dividend per share growth (CAGR)
7.17%
Bulls say / Bears say
Signed a licensing, development and commercialization agreement with Merck for lurbinectedin in Japan, significantly expanding its Asian market footprint (Reuters).
European Commission’s revocation of the initial denial of marketing authorisation for Aplidin has triggered an EMA re-assessment under new impartiality measures, potentially revitalising its multiple myeloma programme (el Economista).
Reported an 18% increase in total revenue and a net profit of €19.4 million in the first half of 2025, driven by robust sales and strategic licence income, markedly improving profitability metrics (GuruFocus).
Withdrew its EU marketing authorisation application for Aplidin on July 23, 2025, amid CHMP concerns over modest efficacy gains and safety, delaying potential approval and market launch (EMA).
Posted a net loss of €3.9 million and an EBITDA deficit of €1.1 million in Q1 2025, versus a €2.3 million profit a year earlier, highlighting profit volatility (el País).
Royalties from U.S. partner Jazz Pharmaceuticals decreased 13% year-on-year to €21.0 million in the first half of 2025, reflecting currency headwinds and heightened competition (MarketScreener India).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharma Mar S.A. stock?
Pharma Mar S.A. (PHM) has a market cap of €1.6B as of September 17, 2025.
What is the P/E ratio for Pharma Mar S.A. stock?
The price to earnings (P/E) ratio for Pharma Mar S.A. (PHM) stock is 0 as of September 17, 2025.
Does Pharma Mar S.A. stock pay dividends?
Yes, the Pharma Mar S.A. (PHM) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is €0.8 and the yield is 0.9%. Pharma Mar S.A. has a payout ratio of 33.2% on a trailing twelve-month basis.
When is the next Pharma Mar S.A. dividend payment date?
The next Pharma Mar S.A. (PHM) dividend payment date is unconfirmed.
What is the beta indicator for Pharma Mar S.A.?
Pharma Mar S.A. (PHM) has a beta rating of -0.09. This means that it has an inverse relation to market volatility.